Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma

Figures & data

Table I. -2841 GLUT1 haplotypes in HCC-tissue of 95 patients in relation to clinicopathological characteristics.

				T allele
Variable	Categorization	n	%	non-carrier	carrier	P*
Clinicopathological characteristics
Age at diagnosis
	<60 years	43	45.3	28	15	0.404
	≥60 years	52	54.7	29	23
Gender
	female	13	13.7	8	5	1.000
	male	82	86.3	49	33
Tumour stage
	pT1	7	7.4	3	4	0.341
	pT2	27	28.4	16	11
	pT3	37	38.9	24	13
	pT4	4	4.2	4	0
	nd	20	21.1	10	10
Histological grade
	G1	24	25.3	13	11	0.484
	G2	45	47.4	28	17
	G3	12	12.6	9	3
	nd	14	14.7	7	7
Tumour size
	≤50 mm	37	33.7	21	16	0.817
	>50 mm	38	46.3	23	15
	nd	20	20.0	12	7

*Fisher's exact test (2-sided); nd, no data available.

Table II. Frequency of the -2841 GLUT1 polymorphism in HCC patients and controls.

-2841 GLUT1 Genotypes	HCC patients n = 95 (%)	Control group n = 127(%)
AA	57 (60.0)	64 (50.4)
AT	34 (35.8)	52 (40.9)
TT	4 (4.2)	11 (8.7)

Figure 1. GLUT1 mRNA expression in HCC with different -2841 GLUT1 haplotypes. GLUT1 mRNA expression was analyzed by quantitative PCR in HCC tissues of patients with (carriers; n = 10) and without (non-carriers; n = 14) the T allele of the -2841 GLUT1 polymorphism. Bars indicate mean ± SEM; (*: p < 0.05).